Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDSBusiness Wire • 11/02/23
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial ResultsBusiness Wire • 11/02/23
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDSBusiness Wire • 09/29/23
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial OfficerBusiness Wire • 09/11/23
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual MeetingBusiness Wire • 09/07/23
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDSBusiness Wire • 08/21/23
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial ResultsBusiness Wire • 08/03/23
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDSBusiness Wire • 06/29/23
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor ImetelstatBusiness Wire • 06/20/23
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDSBusiness Wire • 06/13/23
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS PatientsBusiness Wire • 06/12/23